Gemcitabine intercellular diffusion mediated by gap junctions: New implications for cancer therapy

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Cottin, Sylvine ^a   Ghani, Karim ^a   de Campos Lima, Pedro O ^a   Caruso, Manuel ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

18ALPHA GLYCYRRHETINIC ACID; CISPLATIN; DYE; GANCICLOVIR; GEMCITABINE; TEMOZOLOMIDE; THYMIDINE KINASE; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER INHIBITION; CELL COMMUNICATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DIFFUSION; GAP JUNCTION; GENE EXPRESSION; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; OSTEOSARCOMA CELL; SOLID TUMOR; CELL JUNCTION; FLUORESCENT ANTIBODY TECHNIQUE; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; BYSTANDER EFFECT; CELL LINE, TUMOR; DEOXYCYTIDINE; FLUORESCENT ANTIBODY TECHNIQUE; GAP JUNCTIONS; HUMANS; NEOPLASMS;

EID: 77953246221     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-141     Document Type: Article

References (47)

1. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17(Suppl 5):v7-12. 10.1093/annonc/mdj941, 16807468.
2. Fehlauer F, Muench M, Smid EJ, Slotman B, Richter E, Van der Valk P, Sminia P. Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue. Oncol Rep 2006, 15:97-105.
3. Fabi A, Mirri A, Felici A, Vidiri A, Pace A, Occhipinti E, Cognetti F, Arcangeli G, Iandolo B, Carosi MA, et al. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. J Neurooncol 2008, 87:79-84. 10.1007/s11060-007-9489-x, 17987263.
4. Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 2009, 20:182-187. 10.1093/annonc/mdn543, 18701427.
5. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007, 26:85-110. 10.1007/s10555-007-9044-4, 17345146.
6. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349-4357.
7. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999, 91:1876-1881. 10.1093/jnci/91.21.1876, 10547395.
8. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003, 9:5000-5008.
9. Young JD, Yao SY, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008, 38:995-1021. 10.1080/00498250801927427, 18668437.
10. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990, 38:567-572.
11. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110-6117.
12. van Haperen Ruiz VW, Veerman G, Vermorken JB, Peters GJ. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993, 46:762-766. 10.1016/0006-2952(93)90566-F, 8363650.
13. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988, 48:4024-4031.
14. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007, 96:457-463. 10.1038/sj.bjc.6603559, 2360025, 17224927.
15. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004, 10:6956-6961. 10.1158/1078-0432.CCR-04-0224, 15501974.
16. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006, 66:3928-3935. 10.1158/0008-5472.CAN-05-4203, 16585222.
17. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, Yamazaki H, Eimoto T, Ueda R. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 2007, 256:112-119. 10.1016/j.canlet.2007.06.012, 17658213.
18. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Deviere J, Van Laethem JL. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009, 15:2913-2919. 10.1158/1078-0432.CCR-08-2080, 19318496.
19. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
20. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004, 64:6537-6541. 10.1158/0008-5472.CAN-04-0986, 15374965.
21. Smitskamp-Wilms E, Pinedo HM, Veerman G, van Haperen Ruiz VW, Peters GJ. Postconfluent multilayered cell line cultures for selective screening of gemcitabine. Eur J Cancer 1998, 34:921-926. 10.1016/S0959-8049(97)10125-3, 9797708.
22. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
23. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461. 10.1126/science.1171362, 19460966.
24. Laird DW. Life cycle of connexins in health and disease. Biochem J 2006, 394:527-543. 10.1042/BJ20051922, 1383703, 16492141.
25. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993, 4:725-731. 10.1089/hum.1993.4.6-725, 8186287.
26. Pitts JD. Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol Carcinog 1994, 11:127-130. 10.1002/mc.2940110302, 7945800.
27. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986, 46:5276-5281.
28. Cottin S, Ghani K, Caruso M. Bystander effect in glioblastoma cells with a predominant cytoplasmic localization of connexin43. Cancer Gene Ther 2008, 15:823-831. 10.1038/cgt.2008.49, 18600256.
29. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009, 4:309-324. 10.1038/nprot.2008.226, 19214182.
30. Czyz J, Irmer U, Schulz G, Mindermann A, Hulser DF. Gap-junctional coupling measured by flow cytometry. Exp Cell Res 2000, 255:40-46. 10.1006/excr.1999.4760, 10666332.
31. Goldberg GS, Moreno AP, Bechberger JF, Hearn SS, Shivers RR, MacPhee DJ, Zhang YC, Naus CC. Evidence that disruption of connexon particle arrangements in gap junction plaques is associated with inhibition of gap junctional communication by a glycyrrhetinic acid derivative. Exp Cell Res 1996, 222:48-53. 10.1006/excr.1996.0006, 8549672.
32. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000, 11:1569-1576. 10.1089/10430340050083298, 10945770.
33. Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R, Kunz-Schughart LA. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen 2007, 12:925-937. 10.1177/1087057107306839, 17942785.
34. Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005, 23:964-969. 10.1016/j.orthres.2005.01.010, 16023013.
35. Genc M, Kreder Castro N, Barten-van Rijbroek A, Stalpers LJ, Haveman J. Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin Oncol 2004, 130:45-51. 10.1007/s00432-003-0506-y, 14605880.
36. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991, 27:258-262. 10.1007/BF00685109, 1998982.
37. Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008, 13:261-276. 10.1634/theoncologist.2007-0215, 18378536.
38. Laird DW, Puranam KL, Revel JP. Turnover and phosphorylation dynamics of connexin43 gap junction protein in cultured cardiac myocytes. Biochem J 1991, 273(Pt 1):67-72. 1149880, 1846532.
39. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184. 10.1126/science.2451290, 2451290.
40. Patiar S, Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl 1):S61-75. 10.1677/erc.1.01290, 17259560.
41. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005, 202:1493-1505. 10.1084/jem.20050177, 2213326, 16330813.
42. Mesnil M, Crespin S, Avanzo JL, Zaidan-Dagli ML. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005, 1719:125-145. 10.1016/j.bbamem.2005.11.004, 16359943.
43. Tsai H, Werber J, Davia MO, Edelman M, Tanaka KE, Melman A, Christ GJ, Geliebter J. Reduced connexin 43 expression in high grade, human prostatic adenocarcinoma cells. Biochem Biophys Res Commun 1996, 227:64-69. 10.1006/bbrc.1996.1468, 8858104.
44. Ito A, Koma Y, Uchino K, Okada T, Ohbayashi C, Tsubota N, Okada M. Increased expression of connexin 26 in the invasive component of lung squamous cell carcinoma: significant correlation with poor prognosis. Cancer Lett 2006, 234:239-248. 10.1016/j.canlet.2005.03.049, 15882926.
45. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Tamaki Y, Noguchi S. Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Res Treat 2007, 106:11-17. 10.1007/s10549-006-9465-8, 17203385.
46. Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Maruyama N, Tamaki Y, Noguchi S. Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett 2008, 262:248-256. 10.1016/j.canlet.2007.12.008, 18191019.
47. Asklund T, Appelskog IB, Ammerpohl O, Ekstrom TJ, Almqvist PM. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur J Cancer 2004, 40:1073-1081. 10.1016/j.ejca.2003.11.034, 15093585.